BG106180A - Pharmaceutical composition containing sibutramine and orlistat - Google Patents

Pharmaceutical composition containing sibutramine and orlistat

Info

Publication number
BG106180A
BG106180A BG106180A BG10618001A BG106180A BG 106180 A BG106180 A BG 106180A BG 106180 A BG106180 A BG 106180A BG 10618001 A BG10618001 A BG 10618001A BG 106180 A BG106180 A BG 106180A
Authority
BG
Bulgaria
Prior art keywords
orlistat
pharmaceutical composition
composition containing
containing sibutramine
human
Prior art date
Application number
BG106180A
Other languages
Bulgarian (bg)
English (en)
Inventor
David Heal
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of BG106180A publication Critical patent/BG106180A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG106180A 1999-06-24 2001-12-04 Pharmaceutical composition containing sibutramine and orlistat BG106180A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
PCT/EP2000/005542 WO2001000205A1 (fr) 1999-06-24 2000-06-16 Composition pharmaceutique contenant de la sibutramine et de l'orlistat

Publications (1)

Publication Number Publication Date
BG106180A true BG106180A (en) 2002-08-30

Family

ID=10855955

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106180A BG106180A (en) 1999-06-24 2001-12-04 Pharmaceutical composition containing sibutramine and orlistat

Country Status (21)

Country Link
EP (1) EP1187606A1 (fr)
JP (1) JP2003503349A (fr)
KR (1) KR20020015357A (fr)
CN (1) CN1358092A (fr)
AU (1) AU5533200A (fr)
BG (1) BG106180A (fr)
BR (1) BR0011880A (fr)
CA (1) CA2375972A1 (fr)
CZ (1) CZ20014613A3 (fr)
GB (1) GB9914744D0 (fr)
HK (1) HK1049278A1 (fr)
HU (1) HUP0201878A3 (fr)
IL (1) IL147079A0 (fr)
MX (1) MXPA01012936A (fr)
NO (1) NO20016224L (fr)
PL (1) PL352402A1 (fr)
RU (1) RU2229289C2 (fr)
SK (1) SK18242001A3 (fr)
TR (1) TR200103699T2 (fr)
WO (1) WO2001000205A1 (fr)
ZA (1) ZA200109989B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
RU2007119315A (ru) 2004-10-25 2008-11-27 Зольвай Фармасьютиклз Гмбх (De) Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US7989500B2 (en) 2006-09-15 2011-08-02 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
EP2083867A1 (fr) * 2006-11-22 2009-08-05 SK Chemicals, Co., Ltd. Complexe d'inclusion de sibutramine et de beta-cyclodextrine
CN101890017A (zh) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 含有西布曲明和他汀类降脂药物的药物组合物及其用途
MX336980B (es) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
IN2014MN01407A (fr) 2011-12-30 2015-07-03 Reviva Pharmaceuticals Inc

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
CZ20014613A3 (cs) 2003-04-16
JP2003503349A (ja) 2003-01-28
SK18242001A3 (sk) 2003-02-04
ZA200109989B (en) 2003-02-26
EP1187606A1 (fr) 2002-03-20
WO2001000205A1 (fr) 2001-01-04
KR20020015357A (ko) 2002-02-27
CN1358092A (zh) 2002-07-10
HK1049278A1 (zh) 2003-05-09
HUP0201878A2 (hu) 2003-08-28
IL147079A0 (en) 2002-08-14
RU2229289C2 (ru) 2004-05-27
HUP0201878A3 (en) 2005-04-28
TR200103699T2 (tr) 2002-04-22
GB9914744D0 (en) 1999-08-25
MXPA01012936A (es) 2004-04-21
CA2375972A1 (fr) 2001-01-04
PL352402A1 (en) 2003-08-25
NO20016224L (no) 2002-02-12
NO20016224D0 (no) 2001-12-19
BR0011880A (pt) 2002-03-19
AU5533200A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
GB2254784B (en) Film-coated solid dosage form of anti-migraine drug
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
GEP20043324B (en) Purine Derivatives
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
WO2005056524A3 (fr) Agents therapeutiques pour traitement de la douleur
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
AU3850600A (en) Dalda analogs and their use
GB9305295D0 (en) Therapeutic compounds
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
MX9605458A (es) Derivados de amida y su uso terapeutico.
BG106209A (en) Therapeutic agents
WO2005055933A3 (fr) Nouveau traitement et compositions
MY133438A (en) Morpholinobenzamide salts
AP9801235A0 (en) Erythromycin derivatives.
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
MY126998A (en) Substituted pyrroles.
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors